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Unplanned pregnancies are associated with a higher risk of adverse maternal and 36 
neonatal outcomes, particularly when they occur within a short time interval from a 37 
previous birth.1 Early access to highly effective reversible contraception (implants and 38 
intrauterine contraceptives (IUCs), including both copper intrauterine devices and 39 
levonorgestrel-releasing intrauterine systems) in the postpartum period has been 40 
demonstrated to help women prevent unplanned and rapid-repeat pregnancies.2 We 41 
discuss several compelling reasons for immediate postpartum provision of such methods 42 
to women who desire them.  43 
 44 
IUCs and implants are in the highest tier of contraceptive effectiveness3 because they 45 
require no active adherence on the part of the user. Provision of these methods in 46 
hospital following delivery is particularly attractive because it is convenient for women 47 
who may be particularly motivated to prevent another pregnancy and logistically optimal 48 
in that health professionals trained in method placement could be readily available. 49 
Despite previous concerns, immediate postpartum placement of IUCs and implants is 50 
also extremely safe.4 There is no increased risk of pain, bleeding, infection or uterine 51 
perforation for IUCs placed immediately (within ten minutes of placental delivery) 52 
compared to delayed placement (weeks later). Reported expulsion rates vary widely, 53 
partly due to differences in follow-up intervals and quality of evidence across studies. For 54 
copper-releasing IUCs, immediate postpartum placement is consistently associated with 55 
higher expulsion rates than for delayed placement (1-36.9% versus ~3.0%)5 and the 56 
expulsion rate following immediate placement after Caesarean delivery is consistently 57 
lower than that following immediate placement after vaginal delivery (0-13.9% versus 7.5-58 
22.6%).5 However, these risks seem tolerable given the alternative of no early 59 
contraception cover at all. Up to 41% of women will attempt vaginal intercourse within 60 
six weeks of delivery,8 and among women who are not exclusively breastfeeding, 61 
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ovulation may already have returned by that time or will return soon thereafter.9 Offering 62 
IUCs and implants to all women prior to hospital discharge (or at home, in the case of 63 
home births) would circumvent this problem.10 64 
 65 
The safety of post-delivery placement of IUCs and implants is reflected in the most 66 
recently updated Medical Eligibility Criteria for Contraceptive Use, which provides evidence-67 
based guidance regarding medically eligiblity for specific contraceptive methods. These 68 
guidelines are used by specialists in sexual and reproductive health worldwide to balance 69 
the risks and benefits of contraceptive methods for individual women. The 2009 World 70 
Health Organization Medical Eligibility Criteria (WHO MEC) supports immediate 71 
postpartum placement of levonorgestrel-releasing implants and IUCs for non-72 
breastfeeding women and copper IUCs for all women. Some country-specific MECs 73 
differ regarding the evidence on levonorgestrel and breastfeeding. The 2009 UK MEC 74 
and the 2010 US MEC both support immediate postpartum placement of implants for 75 
all women and the US MEC also extends this guidance to levonorgestrel-releasing IUCs. 76 
 77 
Women who choose immediate postpartum IUCs and implants have a high level of 78 
method satisfaction: US studies have shown high levels of continuation at six and 12 79 
months postpartum (84.3-87.6% and 76.3% respectively for IUCs, and 96.9% and 86.3% 80 
for implants).3 Moreover, for immediate postpartum implant placement, a reduction in 81 
the likelihood of repeat pregnancy within 12 months has also been demonstrated (2.6% 82 
versus 18.6% among women using other methods).3 For immediate IUC placement, a 83 
decision-analysis model based upon data from the US estimated that 88 unintended 84 
pregnancies per 1,000 women would be prevented over two years.6  85 
 86 
In addition to improving women’s health by preventing unplanned pregnancies, 87 
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immediate postpartum provision of IUCs and implants would also save money. The 88 
decision-analysis model of immediate postpartum IUC placement mentioned above 89 
found cost-savings of US$282,540 per 1,000 women who desired a postpartum IUC.6 A 90 
US cost-effectiveness analysis of implants placed prior to hospital discharge following 91 
delivery found cost-savings of US$550,000, US$2.5 million, and US$4.5 million per 1,000 92 
women at 12, 24 and 36 months postpartum respectively.7. 93 
 94 
Implementation of post-delivery IUC and implant services in many countries would not 95 
be without challenges. An initial monetary out-lay would be needed to train the relevant 96 
healthcare professionals in contraceptive counseling and device-fitting. Significant 97 
investments would be required in terms of time, equipment and devices. Yet in the 98 
longer-term, these costs would likely be more than offset by a drop in the medical and 99 
social care cost of unintended pregnancies. In addition, reducing the need for 100 
contraceptive provision appointments in the later postpartum period would lead to time 101 
and cost savings to both women and healthcare systems.   102 
 103 
In light of the Parliamentary Assembly Council of Europe (PACE) resolution on 104 
reducing unintended pregnancy among EU member states11 and the Millennium 105 
Development goal of reducing the worldwide maternal mortality ratio by three-quarters 106 
by 2015,12 widespread adoption of postpartum provision of IUCs and implants 107 
represents an important step towards improving global women’s reproductive health.  108 
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